Glycolysis and Parkinson’s Disease

Abstract

I will review how our work mapping circuits of cognitive control in Parkinson’s disease might lead to targeted biomarkers and interventions. Next, I will describe our new collaborative efforts focused on glycolysis and metabolism in Parkinson’s disease. I will discuss our recent evidence from in vitro models, cell lines, animal models, and large retrospective databases describing how repurposed drugs that enhance glycolysis might lead to disease-modifying therapies for Parkinson’s disease.